Date: 2011-03-10
Type of information: R&D agreement
Compound: novel vaccines
Company: Pepscan Therapeutics (The Netherlands) Crucell (J&J - USA)
Therapeutic area: Infectious diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: Pepscan Therapeutics, the Dutch biotechnology firm focusing on protein mimicry technology, has signed an R&D agreement with Crucell Holland, the Dutch developer of vaccines and antibodies. In the research collaboration, Crucell will make use of Pepscan\'s proprietary technology and know-how in Crucell\'s program for developing undisclosed novel vaccines to combat infectious diseases. Under the terms of the agreement, Pepscan will receive research funding and could receive payments on the achievement by Crucell of research and clinical milestones, as well as royalties on sales of products resulting from the collaboration.
Financial terms: Financial details of the agreement were not disclosed.
Latest news:
